APA citiranje

Cheah, C. Y., Nastoupil, L. J., Neelapu, S. S., Forbes, S. G., Oki, Y., & Fowler, N. H. (2015). Lenalidomide, idelalisib, and rituximab are unacceptably toxic in patients with relapsed/refractory indolent lymphoma. Blood.

Citação norma Chicago

Cheah, Chan Yoon, Loretta J. Nastoupil, Sattva S. Neelapu, Sheryl G. Forbes, Yasuhiro Oki, and Nathan H. Fowler. "Lenalidomide, Idelalisib, and Rituximab Are Unacceptably Toxic in Patients With Relapsed/refractory Indolent Lymphoma." Blood 2015.

MLA citiranje

Cheah, Chan Yoon, et al. "Lenalidomide, Idelalisib, and Rituximab Are Unacceptably Toxic in Patients With Relapsed/refractory Indolent Lymphoma." Blood 2015.